Semax vs Selank: Peptide Nootropic Research Review

Where do Semax and Selank come from?

Semax and Selank both belong to a family of regulatory oligopeptides built around proline-containing sequences called glyprolines, including the tripeptide Pro-Gly-Pro (PGP). A 2005 review from the group behind both compounds argued that glyprolines and related PGP-containing oligopeptides are far more stable in the body than regulatory peptides were thought to be, roughly as stable as major pharmaceutical preparations. It also noted that glyprolines can cross gastrointestinal barriers, and it proposed hybrid ("chimeric") designs that join natural regulatory peptides so that each keeps its own activity while the parts protect one another in vivo ^[7].

Both compounds follow this design. Each joins a short bioactive fragment to a C-terminal Pro-Gly-Pro tail. The fragment is what sets them apart: Semax is based on the ACTH(4-10) fragment, and Selank on tuftsin, an immunomodulatory peptide ^[4]. That shared design and different starting point explains most of the comparison below.

What is Semax?

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, described in the literature as an analog of the adrenocorticotropin fragment (4-10) with reported effects on learning and neuroprotection ^[2]. It is usually classed as a nootropic research peptide. A 2020 neuroimaging paper calls it the "nootropic Semax" alongside the "anxiolytic Selank" ^[5].

The most-cited mechanistic work on Semax looks at brain-derived neurotrophic factor (BDNF) and its receptor trkB. In adult rats given a single dose, hippocampal BDNF protein rose by up to 1.4-fold and trkB tyrosine phosphorylation by 1.6-fold. Exon III BDNF mRNA rose about 3-fold and trkB mRNA about 2-fold. Treated animals also showed a clear increase in conditioned avoidance reactions. The authors proposed that Semax affects cognitive function by modulating the expression and activation of the hippocampal BDNF/trkB system ^[2].

What is Selank?

Selank is a synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, and the literature describes it mainly as an anxiolytic ^{[4] [6]}. Researchers have noted that its range of physiological effects resembles that of the classical benzodiazepines. This has led to work on whether the two share a mechanism ^[3].

In a rat study of the frontal cortex, real-time PCR was used to profile 84 genes involved in neurotransmission, including GABA receptor subunits, transporters, ion channels, and dopamine and serotonin receptors. One hour after administration, Selank produced significant changes in the expression of 45 genes, and 22 genes had changed at 3 hours. At the 1-hour point, the gene-expression changes after Selank correlated positively with those after GABA itself. The authors concluded that Selank has complex effects on nerve cells and suggested allosteric modulation of the GABAergic system as one possible mechanism ^[3].

Semax vs Selank: how do they compare?

The clearest direct comparison is enzymatic. In human serum, both peptides inhibited enzymes that break down enkephalins, and the effect grew with dose. Semax was the more potent inhibitor, with an IC50 of 10 µM against 20 µM for Selank. Both outperformed puromycin, bacitracin and several other peptidase inhibitors. Pentapeptide fragments still inhibited the enzymes, but tri-, tetra- and hexapeptide fragments did not. Because these enzymes also degrade other regulatory peptides, the authors suggested this inhibition may explain part of the biological activity of both compounds ^[1].

Which studies test Semax and Selank side by side?

A 2017 study gave each peptide to rats with 6-OHDA-induced parkinsonism, a model of Parkinson's disease. Neither peptide changed motor activity or passive defensive behavior. Selank reduced anxiety in rats with damaged dopaminergic neurons, matching earlier findings in healthy rodents under psycho-emotional stress. The authors concluded that damage to the substantia nigra does not change the response to Selank ^[4].

In humans, a functional connectomics study scanned 52 healthy participants before administration and at two time points after receiving Semax, Selank or placebo. The analysis centered on the amygdala and the dorsolateral prefrontal cortex in both hemispheres. It found between-group and between-condition differences in resting-state connectivity between the right amygdala and a right temporal cluster covering the fusiform, inferior and middle temporal, and parahippocampal gyri. Post hoc analysis pointed to both general and compound-specific effects of the two peptides ^[5]. These are imaging findings, not clinical outcomes.

What is known about stability and breakdown?

Metabolism research on both compounds has used peptides evenly labeled with tritium, made by high-temperature solid-phase catalytic isotope exchange. With this method, researchers tracked how Selank and its PGP fragment break down in blood plasma and followed Selank in brain tissue. Separate experiments looked at Semax breakdown in the presence of nerve cells. Using labeled [Leu]enkephalin as a substrate, the work also found that Semax strongly inhibited plasma enkephalinases, apparently by acting on aminopeptidases ^[6]. This fits with the serum enzyme findings above ^[1].

The broader glyproline research argues that PGP-containing peptides are more stable than the classical view of regulatory peptides would predict ^[7]. That is a class-level argument. It is not a measured half-life for either compound, and none of the abstracts cited here gives a plasma half-life for Semax or Selank.

How strong is the evidence base?

Most published work on Semax and Selank comes from a small group of related laboratories and uses rodent or in vitro models. Many papers are short reports. Analysts at a Belgian control laboratory looked at two seized preparations and found Selank and Semax in both. They noted that these peptides are presented as cognitive enhancers even though they have not completed clinical trials. They also found them sold online as so-called nootropic research peptides, and they developed and validated an LC-MS/MS method to identify 10 such peptides ^[8].

For research buyers, this means two things. First, identity and purity checks such as mass spectrometry matter, because these compounds already circulate in poorly characterized forms ^[8]. Second, findings from one model, such as BDNF changes in the rat hippocampus or GABA-related gene expression in the rat frontal cortex, should not be assumed to carry over to other systems. All material discussed here is for laboratory research use only.

Frequently asked questions

What is the main difference between Semax and Selank?

They come from different parent peptides. Semax is an ACTH(4-10) analog studied mainly for BDNF/trkB signaling and learning in rodents. Selank is a tuftsin analog studied mainly in anxiety models and for effects on GABA-related gene expression.

Do Semax and Selank share any mechanism?

Yes, in one respect. Both inhibit enkephalin-degrading enzymes in human serum, with reported IC50 values of 10 µM for Semax and 20 µM for Selank. Both also carry the C-terminal Pro-Gly-Pro glyproline motif.

Has anyone compared Semax and Selank directly?

Yes. Studies have compared them in serum enzyme assays, in a rat 6-OHDA parkinsonism model where only Selank reduced anxiety, and in a resting-state fMRI study of 52 healthy participants that found both general and compound-specific connectivity effects.

What is the half-life of Semax or Selank?

None of the PubMed abstracts cited here gives a numeric plasma half-life for either peptide. Tritium-labeling studies have followed their breakdown in plasma, nerve-cell cultures and brain tissue.

Are Semax and Selank approved drugs?

This article does not cover regulatory status. A 2020 forensic analysis noted that these peptides are presented as cognitive enhancers without having completed clinical trials. Material discussed here is for research use only.

Cited studies

1. Kost NV, Sokolov OIu, Gabaeva MV, et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorg Khim. 27(3):180-3 (2001). PubMed 11443939 DOI
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.. Brain Res. 1117(1):54-60 (2006). PubMed 16996037 DOI
3. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.. Front Pharmacol. 7:31 (2016). PubMed 26924987 DOI
4. Slominsky PA, Shadrina MI, Kolomin TA, et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.. Dokl Biol Sci. 474(1):106-109 (2017). PubMed 28702721 DOI
5. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects.. Dokl Biol Sci. 490(1):9-11 (2020). PubMed 32342318 DOI
6. Zolotarev IuA, Dadaian AK, Dolotov OV, et al. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].. Bioorg Khim. 32(2):183-91 (2006). PubMed 16637290
7. Ashmarin IP, Samonina GE, Lyapina LA, et al. Natural and hybrid ("chimeric") stable regulatory glyproline peptides.. Pathophysiology. 11(4):179-185 (2005). PubMed 15837162 DOI
8. Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind.. Drug Test Anal. 12(3):371-381 (2020). PubMed 31667971 DOI